Treatment of pemphigus vulgaris. An overview in Mexico

Allergologia et Immunopathologia

Volumn 34, Issue 1, 2006, Pages 10-16

  Tirado Sánchez, Andrés ^a   Leon Dorantes G ^a  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

Adjuvants; Pemphigus; Pemphigus vulgaris, treatment; Steroids

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CHLORAMBUCIL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DEXAMETHASONE; GLUCOCORTICOID; GOLD SALT; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PREDNISONE; STEROID; TETRACYCLINE DERIVATIVE;

APNEA; AUTOIMMUNE DISEASE; BLADDER CARCINOMA; BONE MARROW SUPPRESSION; DRUG INDICATION; HEMATURIA; HUMAN; INFECTION; MEXICO; MORTALITY; PATHOPHYSIOLOGY; PEMPHIGUS VULGARIS; PHOTOTHERAPY; PLASMAPHERESIS; REMISSION; REVIEW; SEIZURE; SKIN DISEASE;

EID: 33644836300     PISSN: 03010546     EISSN: None     Source Type: Journal    
DOI: 10.1157/13084220     Document Type: Article

References (60)

1. Rosenkrantz WS. Pemphigus: current therapy. Vet Dermatol. 2004;15(2):90-8 (Abs).
2. Brenner S, Mashiah J, Tamir E, Goldberg I, Wohl Y. PEMPHIGUS: an acronym for a disease with multiple etiologies. Skinmed. 2003;2(3):163-7 (Abs).
3. Scott KJ, McKinnon BJ. Pemphigus vulgaris: an acquired blistering disease. South Med J. 2003;96(6):618-20 (Abs).
4. Scully C, Challacombe SJ. Pemphigus vulgaris: update on etiopathogenesis, oral manifestations, and management. Crit Rev Oral Biol Med. 2002; 13(5): 397-408 (Abs).
5. Hashimoto T. Recent advances in the study of the pathophysiology of pemphigus. Arch Dermatol Res. 2003;295 Suppl 1: S2-11 (Abs).
6. Amagai M. Desmoglein as a target in autoimmunity and infection. J Am Acad Dermatol. 2003;48(2):244-52.
7. Martel P, Cordel N, Courville P, Gilbert D, Musette P, Joly P. Pemphigus with clinical, histological and immunological features of both vulgaris and foliaceus subtypes. Br J Dermatol. 2002;147(6):1263.
8. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol. 1977;113(9):1236-41 (Abs).
9. Lever WF, Schaumburg-Lever G. Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. Arch Dermatol. 1984;120(1):44-7.
10. Ratnam KV, Phay KL, Tan CK. Pemphigus therapy with oral prednisolone regimens. Int J Dermatol 1990; 29: 363-7.
11. Ioannides D, Chrysomallis F, Bystryn JC. Ineffectiveness of cyclosporin as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 2000; 136: 868-72.
12. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol 1996; 132: 203-12.
13. Mignogna MD, Lo Muzio L, Ruoppo E, Fedele S, Lo Russo L, Bucci E. High-dose intravenous 'pulse' methylprednisone in the treatment of severe oropharyngeal pemphigus: a pilot study. J Oral Pathol Med. 2002;31(6):339-44 (Abs).
14. Roujeau JC. Pulse glucocorticoid therapy. The 'big shot' revisited. Arch Dermatol. 1996;132(12):1499-502.
15. Chryssomallis F, Dimitriades A, Chaidemenos GC, Panagiotides D, Karakatsanis G. Steroid-pulse therapy in pemphigus vulgaris long term follow-up. Int J Dermatol. 1995;34(6):438-42.
16. Nguyen VT, Arredondo J, Chernyavsky AI, Kitajima Y, Pittelkow M, Grando SA. Pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal effects on keratinocytes. J Biol Chem. 2004;279(3):2135-46 (Abs).
17. Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment of pemphigus vulgaris. J Am Acad Dermatol 1987; 16: 527-33.
18. Tan BB, Lear JT, Gawkrodger DJ, English JS. Azathioprine in dermatology: a survey of current practice in the U.K. Br J Dermatol. 1997;136(3):351-5.
19. Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol 1996; 34: 645-52.
20. Holme SA, Duley J, Anstey AV. Thiopurine methyltransferase screening prior to azathioprine treatment in the United Kingdom. Br J Dermatol 2001; 145 (Suppl. 59): 12
21. Ahmed AR, Hombal S. Use of cyclophosphamide in azathioprine failures in pemphigus. J Am Acad Dermatol. 1987;17(3):437-42.
22. Krain LS, Landau JW, Newcomer VD. Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid. Arch Dermatol 1972; 106: 657-61.
23. Pasricha JS, Sood VD, Minocha Y. Treatment of pemphigus with cyclophosphamide. Br J Dermatol 1975; 93: 573-6.
24. Cummins DL, Mimouni D, Anhalt GJ, Nousari CH. Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol. 2003;49(2):276-80.
25. Pasricha JS, Khaitan BK, Raman RS, Chandra M: Dexamethasone Cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 1995; 34:875-882.
26. Jia GQ, Chen ZQ, Li HL, Cui PG, Xu WY. Weekly cyclophosphamide pulse therapy combined with corticosteroids in the treatment of pemphigus. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2001;23(2):173-5 (Abs).
27. Kanwar AJ, Kaur S, Thami GP. Long-term efficacy of dexamethasone- cyclophosphamide pulse therapy in pemphigus. Dermatology. 2002;204(3):228-31.
28. Sacchidanand S, Hiremath NC, Natraj HV, Revathi TN, Rani S, Pradeep G, Tenneti V. Dexamethasone-cyclophosphamide pulse therapy for autoimmune- vesiculobullous disorders at Victoria hospital, Bangalore. Dermatol Online J. 2003;9(5):2.
29. Pasricha JS, Khaitan BK. Curative treatment for pemphigus. Arch Dermatol 1996; 132: 1518-19.
30. Jain R, Kumar B. Immediate and delayed complications of dexamethasone cyclophosphamide pulse (DCP) therapy. J Dermatol. 2003;30(10):713-8.
31. Grundmann-Kollmann M, Korting HC, Behrens S, Kaskel P, Leiter U, Krahn G, Kerscher M, Peter RU. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol. 1999;40(6 Pt 1):957-60.
32. Liu V, Mackool BT. Mycophenolate in dermatology. J Dermatolog Treat. 2003;14(4):203-11 (Abs).
33. Powell AM, Albert S, Al Fares S, Harman KE, Setterfield J, Bhogal B, Black MM. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol. 2003; 149(1):138-45.
34. Mimouni D, Anhalt GJ, Cummins DL, Kouba DJ, Thorne JE, Nousari HC. Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil. Arch Dermatol. 2003; 139(6):739-42.
35. Chams-Davatchi C, Nonahal Azar R, Daneshpazooh M, Valikhani M, Hallaji Z, Barzegari M, Firouz AR, Zakeri M. Open trial of mycophenolate mofetil in the treatment of resistant pemphigus vulgaris. Ann Dermatol Venereol. 2002;129(1 Pt 1):23-5.
36. Bredlich RO, Grundmann-Kollmann M, Behrens S, Kerscher M, Peter RU. Mycophenolate mofetil monotherapy for pemphigus vulgaris. Br J Dermatol. 1999;141(5):934.
37. Bystryn JC. Is mycophenolic acid effective for the treatment of pemphigus? Arch Dermatol. 1999;135(7):854-5.
38. Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003;149:926-937.
39. Smith TJ, Bystryn JC. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol. 1999;135(10):1275-6.
40. Chen S, Lu X, Zhou G. Mild pemphigus foliaceus responding to combination therapy with niacinamide and tetracycline. Int J Dermatol. 2003;42(12):981-2.
41. Scheinfeld N. A case of co-incident phenylketonuria, pemphigus foliaceus, and tinea amiantacea treated with tetracycline and nicotinamide. J Drugs Dermatol. 2003;2(2):202-5 (Abs).
42. Mueller RS, Fieseler KV, Bettenay SV, Rosychuk RA. Influence of long-term treatment with tetracycline and niacinamide on antibody production in dogs with discoid lupus erythematosus. Am J Vet Res. 2002;63(4):491-4 (Abs).
43. Sawai T, Kitazawa K, Danno K, Sugie N, Machizuki T, Sugiura H, Uehara M. Pemphigus vegetans with oesophageal involvement: successful treatment with minocycline and nicotinamide. Br J Dermatol. 1995;132(4):668-70.
44. Chaffins ML, Collison D, Fivenson DP. Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J Am Acad Dermatol. 1993;28(6): 998-1000.
45. White SD, Rosychuk RA, Reinke SI, Paradis M. Use of tetracycline and niacinamide for treatment of autoimmune skin disease in 31 dogs. J Am Vet Med Assoc. 1992;200(10):1497-500 (Abs).
46. Alpsoy E, Yilmaz E, Basaran E, Yazar S, Cetin L. Is the combination of tetracycline and nicotinamide therapy alone effective in pemphigus? Arch Dermatol. 1995;131(11):1339-40.
47. Hausermann P, Gutersohn T, Beltraminelli H, Schiller P, Buchner SA, Rufli T. Oral pemphigus vulgaris. Successful treatment with minocycline and nicotinamide. Hautarzt. 2002;53(12): 813-5(Abs).
48. Calebotta A, Saenz AM, Gonzalez F, Carvalho M, Castillo R. Pemphigus vulgaris: benefits of tetracycline as adjuvant therapy in a series of thirteen patients. Int J Dermatol. 1999;38(3): 217-21.
49. Gaspar ZS, Walkden V, Wojnarowska F. Minocycline is a useful adjuvant therapy for pemphigus. Australas J Dermatol. 1996;37(2):93-5 (Abs).
50. Hashimoto K, Singer K, Lazarus GS. The effect of corticosteroids, dapsone and gold upon plasminogen activator synthesis and secretion by human epidermal cells cultured with pemphigus antibody. Br J Dermatol. 1984;110(3):293-7.
51. Bjarnason B, Skoglund C, Flosadottir E. Childhood pemphigus vulgaris treated with dapsone: a case report. Pediatr Dermatol. 1998;15(5):381-3.
52. Haim S, Friedman-Birnbaum R. Dapsone in the treatment of pemphigus vulgaris. Dermatologica. 1978;156(2):120-3 (Abs).
53. Leibowitz MR, Voss SP. Juvenile pemphigus foliaceous: response to dapsone. Arch Dermatol. 1993;129(7):910.
54. Pandya AG, Dyke C. Treatment of pemphigus with gold. Arch Dermatol 1998; 134(9): 1104-7.
55. Shah N, Green AR, Elgart GW, et al. The use of chlorambucil with prednisone in the treatment of pemphigus. J Am Acad Dermatol 2000; 42(1 Pt 1): 85-8.
56. Vardy DA, Cohen AD. Cyclosporine therapy should be considered for maintenance of remission in patients with pemphigus. Arch Dermatol 2001; 137(4): 505-6.
57. Levy A, Doutre MS, Lesage FX, et al. Treatment of pemphigus with intravenous immunoglobulin. Ann Dermatol Venereol 2004; 131 (11): 957-61.
58. Mazzi G, Raineri A, Zanolli FA, et al. Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid. Transfus Apheresis Sci 2003; 28(1): 13-8.
59. Gollnick HP, Owsianowski M, Taube KM, et al. Unresponsive severe generalized pemphigus vulgaris successfully controlled by extracorporeal photopheresis. J Am Acad Dermatol 1993; 28(1): 122-4.
60. Nieves Renteria A, Ochoa Fierro JG, Martinez Ordaz VA, et al. Treatment with high doses of intravenous immunoglobulin in a case of complicated pemphigus vulgaris. Rev Alerg Mex 2005;52(1): 39-41.